- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| THESEUS PHARMACEUTICALS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ORUKA THERAPEUTICS | 75,00 | -6,25 % | H.C. Wainwright reiterates Oruka Therapeutics stock rating at buy | ||
| PALVELLA THERAPEUTICS | 123,00 | -6,11 % | Palvella Therapeutics Inc.: FDA Grants Rolling Review of Palvella's QTORIN Rapamycin NDA for Microcystic Lymphatic Malformations | FDA's rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed sections of the NDA before the full application is submitted Palvella remains on... ► Artikel lesen | |
| DIANTHUS THERAPEUTICS | 80,00 | -4,76 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| LENZ THERAPEUTICS | 5,795 | -0,43 % | LENZ Therapeutics, Inc.: LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ in Australia and New Zealand | SAN DIEGO and MELBOURNE, Australia, June 24, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Arrotex Pharmaceuticals Pty Ltd. ("Arrotex") today announced an exclusive license and... ► Artikel lesen | |
| SPYRE THERAPEUTICS | 76,00 | -1,94 % | Spyre falls after $2M insider sale | ||
| KYMERA THERAPEUTICS | 108,12 | 0,00 % | Top Biotech Gainers: TECH Bought Out, MSLE On Watch, KYMR Hits New High, What's The Buzz At SLS? | OTTAWA (dpa-AFX) - Today's top gainers in the biotech space include Bio-Techne, following acquisition news; Satellos Bioscience, gearing up to present new DMD data next month; and Kymera, which... ► Artikel lesen | |
| BICARA THERAPEUTICS | 26,870 | 0,00 % | Bicara Therapeutics Inc.: Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-ß Inhibition in 1L R/M HPV-Negative HNSCC | At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a... ► Artikel lesen | |
| DYNE THERAPEUTICS | 20,940 | 0,00 % | Dyne Therapeutics stock initiated at buy by TD Cowen on platform | ||
| IMMIX BIOPHARMA | 9,980 | 0,00 % | Immix Biopharma, Inc.: Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2 | - Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) - - CR rate now 95% (19 of 20 patients) - - All CRs reached within 1 year of follow-up post-dosing... ► Artikel lesen | |
| ALLOGENE THERAPEUTICS | 2,130 | 0,00 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
| APOGEE THERAPEUTICS | 132,62 | +0,05 % | Apogee Therapeutics: Hier dürfte zum US-Handelsstart heute die Post abgehen! | AbbVie steht laut einem Bericht kurz vor der Übernahme von Apogee Therapeutics für rund 10,9 Milliarden US-Dollar in bar. Der mögliche Aufschlag liegt bei etwa 60 Prozent. Weil die US-Börsen am Freitag... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 94,81 | 0,00 % | Inhibrx Biosciences, Inc.: Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma | No filing review issues identified by FDA with PDUFA goal date set for April 14, 2027
If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 327,29 | -0,15 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| SAB BIOTHERAPEUTICS | 3,800 | 0,00 % | Barclays initiates SAB Biotherapeutics stock at Overweight, PT $13 | ||
| AMYLYX PHARMACEUTICALS | 17,790 | 0,00 % | Amylyx Pharmaceuticals, Inc.: Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026 | Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) ("Amylyx" or the "Company") today announced the presentation of data from its first-in-human, dose-ranging Phase 1 LUMINA trial of AMX0114 at the European... ► Artikel lesen |
Das Unternehmen THESEUS PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu THESEUS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.